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Abstract
Drug-induced orthostatic hypotension (Olf) is a commonside tifftct cfheterocyclic and AfAOI
antidepressant medications. It usually does not respond to conservative treatment and drug
treatments with mineralocorticoids or central dopaminergic antagonists such as metoclopramide
have significant long-term side tifftcts that limit their use. Domperidone, a peripherally acting
dopaminergic antagonist withjew sideeffects, has been used in a number qfsmall clinical trials to
treat OH qf various etiologies. We reviewed 9 studies qf domperidone in the treatment qf OH.
A lthough limited by small sample sizes and poor design, these studiesgenerally showed successful
treatment ofOH by domperidone. Further controlled studies qf domperidone for antidepressant-
induced OH in relevant patient samplesare warranted.
INTRODUCTION
Drug-induced orthostatic hypot en sion (O H), a com mo n side effect of heterocy-
clic a nd mon oamine oxidase inhibitor (MAO I) a n t ide pressan ts, is often encounte red
in clinica l practi ce (1,2). One study found th at seve re sympto matic O H (repeated
fainting or fall ing) occurre d in 9% of pat ients on imi pra mi ne, I I% of patients on
ph en elzin e, and 17% of patients on tranylcypromine (3). The adve rse conseq uen ces of
drug-induced OH are evide nt, particul arly for th e elde rly whe re fa lls can result in
broken hips . Newer ant idepressants suc h as se ro to ne rg ic reuptak e inhibitors do not
ca use significan t blood pressure cha nges. H owever, some patients may need treat-
ment with het erocyclics a nd MAOIs because of refr act ory depression or specificity of
resp onse. For exa m ple, patients may be preferentiall y responsive to MAO Is for
a ne rg ic bipolar depressions (4) or at ypical depression s (5) . Thus, for some patients it
is important to treat side effec ts suc h as OH rather th an to switch to another
a nt ide pressa n t.
Drug-induced OH, however, is ofte n difficult to manage (6). Conservative
treatments su ch as patient educa t ion, vascular s toc kings, increased salt and in-
creased fluid intak e a re usu all y insufficient. Fludrocortison e, a mi ne ra locorticoid
volume expa nde r, has been th e mo st com mo nly used ph armacologic agent for
a n t ide pressan t-induce d OH. Fludrocortison e is effec tive in treating OH, but carries
significan t side effects suc h as resting hyperten sion , hypokalemia and congestive
heart fai lure as well as other possibl e cor t icos teroid effec ts. Dopa mi nergic antago-
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nist s suc h as met aclopramide have been exte ns ively used as a trea t me nt for OH in
Parkinson s disease a nd a uto no mic neurop athies, a nd have also been successful in th e
treatment of MAOI-induced OH (7) . Lik e ot her ph en othiazine drugs, met aclopra-
mide act s ce n trally a nd also has pot entiall y signifi cant side effects including ex tra py-
ramidal sym ptoms, hyperprolactinemia a nd tardive dyskinesia .
Domperidone (trad en am e: Motilium) is a peripheral dop amine a ntagonist th at
does not cross th e blood brain barrier, ha s no ce nt ra l dopaminergic ac t ivity, and
th erefore is devoid of th ese risks (8) . Recently domperidone has been successfully
used in small clinical trials for OH secondary to Pa rk insons disease, diab etic
au to no m ic neuropathy, ce n t ral neurological inju ry a nd d rug-induced OH. T his
a r t icle will review th e lit erature address ing domperidon e as a t reatm ent of OH. O ur
lit erature search revealed only nin e a r t icles focusin g on domperidone a nd ort hostatic
hypot en sion.
Domperidon e is mainly used as an upper gas t ro in tes t ina l mo ti lity agent (9).
Lik e metoclopramide, it has antiem etic a nd gas t ropro kine tic pr operties. Dom peri-
done is gen erally well tol erat ed and has a low incid en ce of side effects, pred omina ntly
dry mouth (1.9 %), headach e (1.2 %), abdo minal cra m ps « 1%), and diarrhea « 1%)
( 10). Althou gh it has no ce nt ral effects it ca n rai se prolacti n levels ( 10). It s usual
dosage ran ge is 30 to 60 mg daily for upper gas troin tes t ina l mot ility d isorders.
Becau se of its a n t ie me tic properties, domp eridone was used to treat the nau sea
a nd eme sis associa te d with dopaminergic agents in th e t reat men t of Pa rkinsons
d isease. The dopamine agoni st a pomo rphine a lso ca uses O H, likely med iat ed
throu gh peripheral , rather th an ce ntra l, dopaminergic mech an ism s ( I I ) . A double-
blind st udy (12) in 4 drug-free patients with Parkinson s disease found th e ac ute
administration of domperidone (100 ug/kg 1M), but not sa line, pr event ed th e
nausea , seda t ion, a nd art erial hypotension seen after apomo rphine injection (20
ug/kg 1M). Poll ack e t al. (13) also st ud ied both th e acute a nd chro nic blood pr essure
effec ts of domperidon e in two se pa ra te stud ies of patients with Parkinsonism. In a
sing le-blind study involvin g 10 patients, domperidon e ( 12 mg 1M) or placebo was
ad ministere d , followed by I mg of a pomo rphine. In th e placeb o condit ion, a pomor-
phine significan t ly lowered supine a nd erect blood pr essures. The domperidone
significa n t ly incr eased supine diastolic blood pr essure, erect systolic a nd diast olic
blood pr essure, and blocked th e hypot en sive effects of a pomo rp hine. T he second
s tudy exa mined th e longer-t erm blood pr essure effects of domperidon e in 16 patients
with idiopathic Parkinson s dis ease chro nica lly treat ed with a variet y of dopa mi nergic
drugs. Five of th ese patients had occasional asymptoma tic OH. Patients were given
eithe r pla cebo or domperidone for on e week in a double blind cross-over design . In
th ese patients domperidon e slightly, but significan t ly, rai sed sup ine systo lic blood
pr essure a nd erect sys tolic a nd diastolic blood pr essure over th e one-week period.
These encouraging results were not supporte d in other s tud ies wit h domperi -
don e a nd brom ocriptine. Agid e t a l. found th at domp eridone (60 mg/day) blocked
bromocriptine-induced nau sea a nd vom iting and allowed for ra pid a ttainme nt of
high th erapeutic dos es of bromocriptine ( 14). There was, however, no protect ion
agains t hypotension in thi s placebo-controlled study. All fou r pa tient s who had
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ort hos tat ic hypoten sion (out of a tot al of 17 subjects) were in th e domperidone group.
Two further reports by th e sa me gro up found th at larger doses of domperidon e (150
mg/day) had no effec t on blood pr essure nor th e occurre nce of ort hos ta t ic hypot en-
sion in 20 patients treat ed with high-dose brom ocriptine ( 15, 16), a lt houg h th ese two
reports se em to consist of th e sa me patient sa m ple. This discrepan cy in results with
bromocriptine a nd a po mo rphine sugges ts th at br om ocriptine-induced postural hy-
pot en sion involves ce n tral mech anisms rather th an peripheral mechan isms.
Althou gh th ese stud ies of domperidon e and dopamine ago nist s have shown
mixed results on blood pr essure effects, clinical stud ies of domperidone in treat ing
OH have ge nera lly been favorabl e. One rep ort found th at domperidone (60 mg/day)
was effec t ive for treating th e OH of3 hypert en sive patients with concurre n t OH from
severa l e t iolog ies (17). Mont astruc c t a l. (I8) looked a t domp erid on c's effec ts in 8
patients with "severe symptoma tic or thosta t ic hypot en sion " of va rious et iolog ies (3
patients had ce ntra l neurological injury, 2 cases had idiopathic OH, a nd 3 pa tien ts
had drug-induced OH du e to clomipramine or antimitotic medi cation ). Aft er 5 days
of treatment with domperidone OH improved a nd sympto ms disappea red in all
cases. Aft er 5.0 ± 1.4 months mean follow-up th e orthos ta tic d rop was significan t ly
reduced from 53.1 ± 4 mmHg before treatment to 25.0 ± 9.5 mmHg afte r
domperidone. Domperidone ha s a lso been effect ive in treating symptomatic OH in
diabetic a utonomic neuropathy (19). Lopes de Faria et a l. (20) stud ied 9 patients with
diab etic a uto no m ic neuropathy a nd showed th at ora l domperid one 30 mg/day for 3
days significa n t ly decreased th e orthos ta tic drop in blood pr essure. Six of th ese
patients maintained th eir im proveme nt a fte r a 6-mo nth follow-up.
DISCUSSIO T
The mech anism of ac t ion of domperidon e on blood pressure rem ains poorly
underst ood . Peripherally ac t ing dopamine may have vasod ilat ing and naturieti c
effects, and excessive dopamine release up on sta nd ing has been described in pat ient s
with OH (2 1). Met oclopramide is hypothesized to inhibit th ese effec ts and increase
plasma levels of aldosterone and free epinephrine (22) . Domperidon e's peripheral
dopaminergic blockad e may have simila r effec ts . Domperidon e is a lso a spec ific
a n tagonist of D2 pr esynaptic dopamine receptors (23) . Since norepinephrine release
is inhibited by dopaminergic activity on D2 receptors, domperidon e 's effec t on O H
may be mediated through enha nce me nt of peripheral noradren ergic act ivity. Prel im-
inary stud ies, however, have not found significa n t incr eases in plasm a renin act ivity,
ald ost erone, responsiven ess to a ng iote ns in II , nor urinary ca techo lam ines th at might
explain th e postural blood pr essure cha nges followin g domperidon e (20) .
In sum mary, this review indi cates that domperidon e was effect ive in t he treat-
ment of sym ptoma tic OH du e to varied ca uses including diab etic neu ropat hy, ce ntral
neurological inju ry, Parkinsoni sm a nd some drug-induced OH. However, t hese
stud ies a re limited by small sample sizes, ope n clinica l design s, a nd th e inclu sion of
mult iple et iologies for OH. one compared domp eridon e to othe r effec t ive treat -
ments for OH. The mechanism for domperidon e's act ion on blood pressu re is
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unknown, so domperidone may be effec t ive only for ce rtain et iolog ies of OH. Only
on e patient in th ese stud ies had a nt ide pressan t-induce d OH. However, he terocyclic
and MAOI a ntide press a n ts cont inue to be essen t ia l tools in our psychopharmacologic
a rmame nta r ium, despit e th eir hypot en sive side effec ts . For some patients with
antidepressant-induced OH, particul arly th ose who did not respond to antidepres-
sa n ts th at do not have OH as a side effect, it will be clinica lly advantageous to treat
th e OH rather than switching drugs. Becau se domperidon e is a we ll-tolerated
medi cation with few side effec ts, it will be worthwhile to det ermine in controlled
s tud ies wh ether it is a n effec t ive treatment for antidepressant -induced O H in these
patients. Sin ce OH ca n be sympto matic or asy mpto matic, tra nsient or continuous,
future clinical stud ies should ope ration aliz e th e defin iti on and measurement of OH
in orde r to det ermine th e clinical versu s statis t ica l sign ifica nce of t rea tments.
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